Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Gao, NJ
Dayuan Gao, East Brunswick, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110268803 | LUNG TARGETING DUAL DRUG DELIVERY SYSTEM - The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases. | 11-03-2011 |
He Gao, Plainsboro, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20080213418 | ALIGN-TRANSFER-IMPRINT SYSTEM FOR IMPRINT LITHOGRPHY - An imprint system for imprint lithography comprises an alignment subsystem and an imprint subsystem. The mask (mold) and the wafer for imprinting (substrate) are align on the alignment subsystem and contacted to each other to form a mask/wafer set. The mask/wafer set is then transferred onto the imprint subsystem while alignment is maintained. The mask/wafer set is then imprinted on the imprint subsystem. During transfer, the mask/wafer set can be held in alignment by surface. The surface adhesion can be enhanced by local pressing, local heating, or both. Alternatively, the mask/wafer set can be held in alignment by clamping. Advantageously, the imprinting is effected by fluid pressure imprinting. | 09-04-2008 |
Hong Gao, Belle Mead, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20080200541 | Benzofuranyl Alkanamine Derivatives and Uses Thereof - Compounds of formula I or pharmaceutically acceptable salts thereof are provided: | 08-21-2008 |
| 20090082434 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same - Compounds of Formula 1 or pharmaceutically acceptable salts thereof are provided: | 03-26-2009 |
Ji Gao, Cranbury, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110269139 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO EPIDERMAL GROWTH FACTOR RECEPTOR MODULATORS - The present invention provides methods useful for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, and diagnostic methods and kits thereof. | 11-03-2011 |
Julia Zh Gao, Plainsboro, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20080275009 | ORAL ADMINISTRATION OF N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-1,3-THIAZOLE-5-CARBOXAMIDE AND SALTS THEREOF - Disclosed are a method of treating cancer and/or other proliferative diseases comprising orally administering N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof, and pharmaceutical compositions comprising N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof. Also disclosed are N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide salts, as well as crystalline forms thereof. | 11-06-2008 |
Min Gao, Edison, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20080213817 | Enhancement of Th2-Dependent and Inflammatory Response - The present invention relates to altering the levels of Th2 cytokine production, and in particular, biasing the cytokine expression profile towards Th2 cytokine production through mitogen-activated protein kinase/ERK kinase kinase 1 (MEKK1), the screening of agents that increase Th2 cytokine production, and the treatment of Th1 associated autoimmune diseases in vivo. In one embodiment, the present invention relates to agents including but not limited to reducing the activity of MEKK1, leading to increased levels of Th2 cytokine production. | 09-04-2008 |
Xiaolei Gao, Scotch Plains, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090118284 | Novel compounds that are ERK inhibitors - Disclosed are the ERK inhibitors of formula 1.0: | 05-07-2009 |
Xiaolei Gao, Kenilworth, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110189192 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS - Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. | 08-04-2011 |
Xiaolei Gao, Bridgewater, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110038876 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS - Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. | 02-17-2011 |
Xingtao Gao, Edison, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110139684 | Catalyst Composition for Reducing Gasoline Sulfur Content in Catalytic Cracking Process - A sulfur reduction catalyst useful to reduce the levels of sulfur in a cracked gasoline product comprises a metal vanadate compound. The metal vanadate compound can be supported on a molecular sieve such as a zeolite in which the metal vanadate compound is primarily located on the exterior surface of the pore structure of the zeolite and on the surface of any matrix material used to bind or support the zeolite. | 06-16-2011 |
Xintao Gao, Edison, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110243837 | Method for Making Mesoporous or Combined Mesoporous and Microporous Inorganic Oxides - A method for making a mesoporous or combined mesoporous/microporous inorganic oxide includes reacting a source of inorganic oxide with a complexing agent at a complexation temperature to provide a complex; decomposing the complex to provide a porous material precursor having an inorganic oxide framework containing at least some organic pore-forming agent; and removing the organic pore forming agent from the inorganic oxide framework by solvent extraction and/or calcination. | 10-06-2011 |
Xuerong Gao, Livingston, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090188555 | Conductive Inks With Metallo-Organic Modifiers - A conductive ink having a glass frit, an organic medium a conductive species and one or more metallo-organic components which form metal oxides upon firing and reduce series resistance to a same or greater degree a ink that do not include metallo-organic components, is provided. Embodiments of conductive ink include metallo-organic components that include a bismuth metallo-organic component and glass frits comprising one or more of bismuth oxide, silica, boron oxide, tellurium dioxide, and combinations thereof. Embodiments of photovoltaic cells with an anti-reflection coating, gridlines formed from conductive ink incorporating one or more metallo-organic components, are also provided. | 07-30-2009 |
| 20090188556 | Conductive inks - A conductive ink substantially free of frit and photovoltaic cells having conductive gridlines formed from a conductive ink substantially free of glass frit are described. Conductive inks according embodiments of the present invention are adapted to adhere to the surface of a substrate and, upon firing, form a solid metal oxide phase and cause a conductive species to form an electrical conductor on the substrate. In further embodiments, the conductive ink is capable of penetrating anti-reflection coatings disposed on surfaces of substrates. In accordance with one or more embodiments, the conductive inks include a plurality of metallo-organic components which form a solid metal oxide phase upon firing and a conductive species. In other embodiments, the conductive inks include a plurality of precursors, including one or more precursors which form conductive elements upon firing or heating. | 07-30-2009 |
| 20100193494 | Conductive Compositions - A conductive composition having a conductive component, a glass frit component, an organic medium, a boride component and a platinum group metal component, is provided. Embodiments of the conductive composition incorporate a palladium component and boride component selected from ZrB | 08-05-2010 |
Ying-Duo Gao, Edison, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090105210 | Bicyclic Pyrimidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes - The present invention is directed to novel substituted bicyclic pyrimidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 04-23-2009 |
| 20100317645 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS - Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes. | 12-16-2010 |
Zhongli Gao, Bridgewater, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110251225 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I): | 10-13-2011 |
| 20110257213 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 10-20-2011 |
Zhongli Gao, Flemington, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20100173897 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 07-08-2010 |
| 20100173898 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides of formula (I). | 07-08-2010 |
| 20100173908 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine ureas of formula (I). | 07-08-2010 |
| 20100173949 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 07-08-2010 |
| 20100179154 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to the 6-cycloamino-3-(pyridin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): | 07-15-2010 |